Introduction
We have examined the capacity of the major cytoplasmic membrane protein (MCMP) of Legionella pneumophila, a genus common antigen and member of the hsp 60 family ofheat shock proteins, to induce protective immunity in a guinea pig model of Legionnaires' disease. We purified MCMP to homogeneity from L. pneumophila by buffer extraction, ion-exchange chromatography, and molecular sieve chromatography.
Guinea pigs immunized with MCMP developed a strong cell-mediated immune response to the immunogen manifest by marked cutaneous delayed-type hypersensitivity. Guinea pigs immunized with MCMP and then challenged with a lethal aerosol dose of L. pneumophila exhibited a high level of protective immunity. Altogether, in four independent experiments, 55 of 64 (86%) animals immunized three times with 0.6-40 yg MCMP including 11 pneumophila compared with 1 of 29 (3%) sham-immunized control animals (P < 0.0001, Cochran-Mantel-Haenszel x2 statistic for pooled data).
To our knowledge, MCMP is the first member ofthe hsp 60 family of proteins shown to induce protective immunity to a microbial pathogen. MCMP has potential as a vaccine against Legionnaires' disease. Since MCMP is a genus common antigen, vaccination with a combination of MCMPs derived from different Legionella species has the potential of inducing protective immunity against all the major Legionella species causing human disease. (J. Clin. Invest. 1993. 91:717-723.) Key words: vaccine * immunoprotective determinants * cell-mediated immunity intracellular parasitism -heat shock protein Subunit vaccines are a major goal of modern vaccine research. Such vaccines, consisting ofone or a few molecules or epitopes, offer several potential advantages over traditional whole cell vaccines, generally consisting ofavirulent or killed microorganisms. First, by focusing the immune system on a few key immunoprotective determinants, rather than on a complex mix of a few relevant and many irrelevant molecular species, the subunit vaccine might attain greater protective efficacy. Second, by excluding molecular species capable of inducing suppression of an immune response, the subunit vaccine might allow the immune system to respond to immunoprotective moieties otherwise unable to induce protection in the midst of whole cell vaccines. Third, by being composed of a limited repertoire of molecular species, the subunit vaccine might be less likely to induce allergic or toxic reactions than whole cell vaccines.
Intracellular pathogens constitute a special challenge to the immune system and vaccine development. A successful vaccine must enable the host immune system to recognize infected host cells and mount an effective antimicrobial response against pathogens sequestered within them. The host immune system generally accomplishes this via cell-mediated immune mechanisms, such as those leading to the proliferation of antigen-specific lymphocytes capable ofactivating infected macrophages or exerting a cytotoxic effect against them. For this reason, microbial components that induce strong cell-mediated immune responses are potentially immunoprotective.
This laboratory has been investigating immunoprotective molecules of the intracellular pathogen Legionella pneumophila, the agent of Legionnaires' disease. Cell-mediated immunity plays a central role in host defense against L. pneumophila, whereas humoral immunity does not appear to play a significant role (1) (2) (3) (4) . In a previous study, we reported that the major secretory protein (MSP)' of L. pneumophila induces cell-mediated immune responses and protective immunity against a lethal aerosol challenge with L. pneumophila in the guinea pig model of Legionnaires' disease (5). Interestingly, this molecule, although immunoprotective, is not a virulence determinant in the guinea pig model (6) . This demonstrates that, in the case of an intracellular pathogen, vaccinogens can induce protective immune responses that function in ways other than by neutralizing virulence determinants, such as by enhancing the capacity ofthe immune system to detect and respond effectively against infected host cells. The major secretory protein is capable of inducing protective immunity across at least some serogroups of L. pneumophila, but not necessarily across species in the family Legionellacea, including some that cause pneumonia (7). The major secretory protein also does not induce protection against strains of L. pneumophila and species of Legionella that do not secrete the protein (7) . These limitations of the major secretory protein prompted a search for other immunoprotective molecules of L. pneumophila.
Subsequently, we demonstrated that L. pneumophila membranes induce protective immunity independent of the major secretory protein (8) . However, the identity ofimmunoprotective components of the membranes remained to be determined. To identify such components, we focused our attention on native membrane antigens recognized by immune lymphocytes. Using the T cell Western blot technique (9, 10), we noted in preliminary studies that immune lymphocytes from guinea pigs immunized with a sublethal dose of aerosolized L. pneumophila responded more strongly than control lymphocytes to a protein in the region ofthe 65-kD major cytoplasmic membrane protein (MCMP). We also determined that guinea pigs immunized with purified MCMP, but not sham-immunized control animals, developed a strong cell-mediated immune response to the protein, manifest by cutaneous delayedtype hypersensitivity. These findings suggested that MCMP may have immunoprotective potential.
MCMP was so designated in an early study from this laboratory that demonstrated that this molecule was the major protein species in the cytoplasmic membrane fraction isolated from cell envelopes ofL. pneumophila by isopycnic centrifugation ( 11) . More recently, immunoelectron microscopy studies in this laboratory using monospecific affinity-purified anti-MCMP antibody have demonstrated that the great majority of MCMP in the bacterial cell is associated with the bacterial membrane ofL. pneumophila, whereas the amount in the cytoplasm is minimal (Clemens, D. L., E. Shang, and M. A. Horwitz, unpublished data). Our early study also showed that MCMP was the major protein species ofL. pneumophila recognized by antibody in convalescent sera of patients recovered from Legionnaires' disease (11) . Subsequently, studies by other investigators have demonstrated that this protein is a genus common antigen and a member of the hsp 60 family of heat-shock proteins (12) (13) (14) .
In the present study, we have purified MCMP and examined its immunoprotective capacity. We shall demonstrate that immunization with MCMP induces protective immunity against lethal aerosol challenge with L. pneumophila.
Methods
Media. Albumin yeast extract broth, and egg yolk buffer with or without 1% BSA (Miles Laboratories Inc., Naperville, IL) were prepared as previously described ( 15) . RPMI 1640 with L-glutamine (Gibco Laboratories, Grand Island, NY) was mixed with penicillin ( 100 U/ml) and streptomycin (100 ug/ml) (Gibco Laboratories).
Agar. Modified charcoal yeast extract agar (CYEA) was prepared as described (15) . Modified CYEA without cysteine and tryptic soy agar with 5% sheep blood were used to assay for contaminating bacteria.
Bacteria. L. pneumophila, Philadelphia 1 strain (serogroup 1), was grown in embryonated hens' eggs, harvested, tested for viability and the presence of contaminating bacteria, passed one time only on CYEA, washed with egg yolk buffer, flash frozen in aliquots of 10 " CFU/ ml, and stored at -700C ( 15) . Before use in the aerosol inoculation system, a stock preparation of bacteria was diluted in EYB to the desired concentration.
Purification ofMCMP. L. pneumophila was grown on CYEA and harvested into an extraction buffer consisting of 0.05 M Tris, 0.01 M EDTA, 0.02 M MgSO4, pH 8.0, 0.0005% DNase, and 0.024% lysozyme. The suspension was shaken at 100 rpm for 1 h at room temperature and centrifuged at 16,000 g for 10 min at 4VC to pellet the bacteria. The supernate, containing extracted MCMP and other molecules, was filtered through 0.45-,gm low protein binding filters (Tuffryn; Gelman Sciences, Inc., Ann Arbor, MI) to remove residual bacteria. The pellet was resuspended in extraction buffer and the above procedure repeated once. The filtrates from the two extraction procedures were combined and applied to a 2.5 x 13-cm Sepharose CL-6B column (Pharmacia Fine Chemicals, Piscataway, NJ), and a gradient of 0.1-0.25 M NaCl in 0.05 M Tris containing 0.01 M EDTA was applied at a flow rate of 10 ml/h using a gradient maker (Pharmacia Fine Chemicals) with 2.5 bed volumes in each chamber. Fractions containing the 65-kD MCMP, eluting at 0.17 M NaCl, were identified by SDS-PAGE (16) and pooled.
In initial studies, MCMP was purified in the final step by affinity chromatography using monospecific rabbit or guinea pig anti-MCMP antibody eluted from strips oftransfer membranes (Immobilon; Millipore Corp., Bedford, MA), to which electrophoretically purified MCMP was transferred. In later studies, MCMP was purified in the final step by a simpler procedure, molecular sieve chromatography, as follows: Ion exchange purified MCMP was concentrated (Centriprep 30; Amicon, Beverly, MA), dialyzed against 0.05 M Tris, 0.01 M EDTA, and 0.1 M NaCI, pH 8.0, and applied to a 2.6 X 70-cm Sephacryl S-400 HR column. The column was eluted with the same buffer at a flow rate of 240 ml/h. Fractions containing MCMP were pooled, concentrated with Centriprep 30, dialyzed against PBS, and stored at 4VC under nitrogen until use.
Mass and purity ofMCMP. The mass of MCMP was measured with a bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, IL) using BSA as a standard. The purity of MCMP was assessed by SDS-PAGE by applying 10 ,g ofpurified MCMP to a 12.5% gel and staining with Coomassie brilliant blue R and by NH2-terminal sequencing. Protein sequencing was performed at the University ofCalifornia at Los Angeles Protein Microsequencing Facility.
Localization ofMCMP in the L. pneumophila envelope. L. pneumophila membranes were prepared as previously described (8, 11) . Briefly, whole L. pneumophila cells were converted to spheroplasts by treatment with lysozyme and EDTA, the spheroplasts were lysed osmotically, and the cell envelopes were resolved into inner and outer membrane fractions by isopycnic (sucrose density gradient) centrifugation ( 11) . The membrane fractions were subjected to SDS-PAGE and analyzed by immunoblot analysis as described (8, 17) . For immunoblot analysis, monospecific anti-MCMP antibody was prepared by immunizing rabbits with purified MCMP, collecting the antiserum, binding the anti-MCMP antibody to purified MCMP that had been subjected to SDS-PAGE and transferred to Immobilon transfer membranes (Millipore Corp.), and eluting the monospecific antibody from the membranes. The second antibody was alkaline phosphataseconjugated goat anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO), and the enzyme substrate solution used for visualization consisted of nitroblue tetrazolium and 5-bromo-4-chloro-indolyl-phosphate in anhydrous dimethyl formamide in 0.05 M Tris and 0.003 M MgCl2, pH 10, as described (8) .
Animals. Male Hartley strain guinea pigs weighing 250-300 g (Simonson Laboratories, Gilroy, CA), were cared for as previously described ( 18) . They were observed in the vivarium for 1 wk before challenge with L. pneumophila to ensure that they were healthy. No illnesses or deaths occurred in the guinea pigs before challenge.
Immunization ofguinea pigs with MCMP. Guinea pigs were immunized with MCMP three times at 2 3 wk intervals. MCMP was dialyzed in PBS and mixed 1:1 in CFA for the first injection, and in incomplete Freund's adjuvant for the second and third injections. The injection sites of the guinea pigs were washed with 70% ethanol and the animals were injected subcutaneously with 40, 10, 2.5, or 0.6 Mg of MCMP. Control animals were sham immunized at the same time with normal saline in CFA (first injection) or incomplete Freund's adjuvant (subsequent injections).
Cutaneous delayed-type hypersensitivity assay. Guinea pigs were shaved over the back and flank and administered 0, 1, or IO Lg MCMP in a total volume of 100 Ml PBS intradermally. The diameters or erythema and induration were measured 24 h later. Protective immunity. Guinea pigs were challenged by exposure to aerosols containing wild-type L. pneumophila in an aerosol chamber described in detail in a previous study (4) . Guinea pigs were challenged 3-5 wk after immunization with a 100% lethal dose of aerosolized wild-type L. pneumophila. This dose, which was generated from a 10-ml suspension of wild-type L. pneumophila containing 1-2 X l0 CFU/ml, was the lowest dose that consistently resulted in the death of nonimmunized guinea pigs, as previously described (4). After challenge, animals were held in filter-top cages for 10 d. During this time they were observed for signs of illness, and survival was quantitated. Differences in survival between immunized and control animals within experiments were evaluated by computing exact permutational P values (StatXact software; Cytel Corp., Cambridge, MA). For pooled data, differences in survival between immunized and control animals were evaluated by the Cochran-Mantel-Haenszel x2 statistic.
Results
Purification of MCMP. We initially purified MCMP by a three-step process involving buffer extraction from whole L. pneumophila, ion-exchange chromatography, and affinity chromatography. SDS-PAGE analysis of the purified MCMP yielded a single band ofapparent molecular mass of60-65 kD, suggesting a high degree ofpurity, and this material was used to immunize animals in initial challenge experiments (experiments A and B, Table I ). Subsequently, NH2-terminal sequence analysis of MCMP purified by affinity chromatography in the final step revealed the presence of serum albumin in the preparation. Although the presence ofalbumin was unlikely to influence the results of the challenge experiments in a qualitative way, it complicated the determination of MCMP concentration in the immunizing dose. We therefore developed an alternative purification procedure using molecular sieve chromatography rather than affinity chromatography in the final step of purification. The purified MCMP obtained by this simpler procedure also exhibited a single band ofapparent molecular mass of 60-65 kD on SDS-PAGE analysis (Fig. 1 , lane E), suggesting that it was > 99% pure. Moreover, NH2-terminal sequence analysis of this preparation revealed a pure protein and the sequence of the 40 NH2-terminal amino acids exactly matched the deduced sequence derived from the published nucleotide sequence of MCMP (19, 20) , otherwise known as the 60-kD common antigen and member of the hsp 60 heat shock protein family. We repeated the challenge experiments (experiments C and D, Table I ) using this preparation of purified MCMP. Localization ofMCMP to the cytoplasmic membrane. The fact that milligram quantities of MCMP were purified from a small number ofplates ofbacteria implied that MCMP was one ofthe three major proteins ofL. pneumophila cells. Only one of these proteins, the major protein species in the cytoplasmic membrane, has a molecular weight similar to or even near that of purified MCMP. To confirm the identity of MCMP as this cytoplasmic membrane protein, we examined purified MCMP and purified L. pneumophila cytoplasmic and outer membranes by SDS-PAGE and immunoblot analysis. Purified MCMP migrated to the same extent as the major species ofthe cytoplasmic membrane on SDS-PAGE gels (Fig. 2 A) . Moreover, on immunoblot analysis of the cytoplasmic membrane ( Fig. 2 B, Fig. 2 B, lane B) . Taken together, these data demonstrate that the purified protein was the same as the major protein species of the cytoplasmic membrane, previously designated MCMP.
Guinea pigs immunized with MCMP develop a cutaneous delayed-type hypersensitivity response to MCMP. To determine if MCMP-immunized guinea pigs develop a cell-mediated immune response to the immunogen, we skin-tested the animals after immunization. In three independent experiments, MCMP-immunized animals consistently exhibited stronger skin test responses than sham-immunized control guinea pigs, with markedly greater erythema and induration (Table II) . The mean extent of erythema in MCMP-immunized animals was 1.8 times to infinitely greater than that in sham-immunized animals. With one exception (the lower dose tested in experiment C), the mean extent ofinduration was 3.7 times to infinitely greater than that in sham-immunized controls. In the one experiment in which animals were immunized with different doses of MCMP (ranging from 0.6 to 40 Mug), the MCMP-immunized animals exhibited a clear-cut dose-dependent response to MCMP on skin testing; i.e., the higher the immunizing dose, the greater the extent oferythema and induration in response to MCMP (Table II, 
experiment B).
Guinea pigs immunized with MCMP are protected against lethal aerosol challenge with L. pneumophila. To determine if guinea pigs immunized with MCMP are protected against lethal aerosol challenge, we immunized guinea pigs three times with 0.6-40 ug of MCMP, and 3-5 wk later, we challenged MCMP-immunized and sham-immunized animals with a lethal aerosol dose of L. pneumophila. In four independent experiments, guinea pigs immunized with MCMP demonstrated significantly greater survival than control animals (Table I). Overall, 55 of64 (86%) animals immunized with 0.6-40 MAg doses of MCMP survived, compared with 1 of 29 (3%) control animals (P < 0.0001, Cochran-Mantel-Haenszel x2 statistic for pooled data). Of animals immunized with 40 Mg MCMP, the highest dose tested, 11 of 11 ( 100%) survived challenge compared with 1 of 16 (6%) control animals in these experiments (experiments C and D, Table I) (P < 0.0001 ). In experiment A (Table I) , as a positive control, one group of animals was immunized with a sublethal dose of L. pneumophila, previously shown to induce protective immunity (4) . These animals exhibited a higher level of protective immunity (100%) than MCMP-immunized animals (67%) but this difference was not statistically significant. In subsequent experiments (experiments B-D, Table I ), animals immunized with the higher doses of MCMP also exhibited 100% protection.
Immunized animals first exhibited signs ofillness including decreased activity and respiratory distress 1 d after challenge, but most then recovered. This response in immunized animals was clearly dose-dependent (40 > 10 > 2.5 > 0.6 ,g immunizing dose) in the two experiments (experiments C and D, C) were subjected to SDS-PAGE and electrophoretically transferred to nitrocellulose membranes. Lanes A and B were stained with amido black. Lane C was incubated with monospecific anti-MCMP antibody and the bound antibody visualized using alkaline phosphatase-conjugated goat anti-rabbit IgG as described in the text. In three independent experiments, guinea pigs were immunized subcutaneously three times with 0.6-40 ,g MCMP, as indicated, or sham immunized. 3-5 wk later, the animals were skin tested with an intradermal dose of 1 Ag MCMP (experiments A and B) or both 1 and 10 Ag MCMP (experiment C). The extent of erythema and induration at skin test sites was measured 24 h later. Neither immunized nor control animals developed erythema or induration in response to the PBS buffer in which the MCMP skin test antigen was diluted. * SI, stimulation index = (mean skin reactivity of immunized guinea pigs)/(mean skin reactivity of control guinea pigs).
recover. All animals surviving 10 d after challenge recovered fully from earlier signs of disease.
In experiments C and D (Table I) , in which animals were immunized with doses ofMCMP ranging from 0.6-40 ,g, even the lowest immunizing dose was highly protective against death. However, protection against illness in these experiments was clearly dose-dependent. All (19, 20) . The gene encoded a mature protein of 547 amino acids, which Sampson et al. determined had a computed molecular mass of 57,952 D (19) .
As other species of Legionella also contain this genus common antigen, vaccination with the MCMP molecules derived from these species may similarly induce protective immunity against the homologous species. Thus, a combination of MCMP molecules from different legionella species has the potential of inducing protective immunity against all legionella species that are major causes of human disease. Furthermore, because MCMP is a genus common antigen that may contain shared T cell as well as B cell epitopes, MCMP may induce protective immunity across species of Legionella; i.e., MCMP from some species ofLegionella may protect against other species of Legionella in addition to the homologous species.
MCMP is the second protein molecule of L. pneumophila that we have found to be immunoprotective by itself. As noted in the introduction, MSP is also highly immunoprotective. As immunogens, both MCMP and MSP may have advantages in different settings, and a vaccine combining them might be more efficacious than one containing only one of the proteins.
As noted above, MCMP is a heat-shock protein and member ofthe hsp 60 family ofsuch proteins. Heat-shock proteins including the hsp 60 family have frequently been found to be immunodominant molecules of intracellular pathogens. Thus, for example, the 65-kD proteins of M. tuberculosis and M. leprae are major T cell and B cell antigens (23, 24) and the 57-kD heat shock protein of Chlamydia trachomatis elicits a strong humoral immune response in human infection (25 ) and cell-mediated inflammatory response in a guinea pig model of chlamydial ocular infection (26) . To our knowledge, MCMP is the first member of the hsp 60 family shown to induce protective immunity (27) .
The hsp 60 or GroEL family ofheat shock proteins is a very conserved group and a high level of homology (50-60% sequence identity) exists between human and bacterial hsp 60 proteins, including Legionella hsp 60 protein ( 19, 20, 27, 28) . This has raised the question as to whether microbial hsp 60 proteins might play a role in autoimmune disease. In support of this idea, T cells reactive with the mycobacterial hsp 65-kD protein, a member ofthe hsp 60 family, have been found in the synovial fluid ofpatients with rheumatoid arthritis and reactive post-infectious arthritis (29, 30) . Also, in the rat model ofadjuvant-induced arthritis, a T cell clone capable of causing severe arthritis upon transfer to heavily irradiated recipients recognizes an epitope of the mycobacterial hsp 65-kD protein (31, 32) . However, T cells reactive to self epitopes of the hsp 60 protein and antibody to conserved epitopes of hsp 60 protein have been identified in normal healthy individuals (33, 34) , indicating that the mere existence of hsp 60 reactive T and B cell clones in an individual is not necessarily associated with disease.
While T cells reactive with hsp 60 proteins may be involved in autoimmune disease, there is no evidence that immunization with purified hsp 60 proteins induces chronic autoimmune disease. In fact, to the contrary, there is evidence that immunization with these proteins protects against autoimmune disease. Pretreatment of rats with a mycobacterial hsp 65-kD protein protects against adjuvant-induced arthritis and against streptococcal cell wall-induced T cell dependent polyarthritis (31, 35, 36 
